[6-K] Tiziana Life Sciences Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Tiziana Life Sciences (TLSA) reported that its Phase 2 clinical trial of intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham. This places the company’s ALS study within a coordinated clinical research framework focused on the disease. The update is structured as an informational report and does not include financial results or transaction details.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

November 2025

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On November 25, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted for inclusion in the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: November 25, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated November 25, 2025

3

FAQ

What did Tiziana Life Sciences (TLSA) announce in this 6-K?

Tiziana Life Sciences announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted for inclusion in the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham.

What is the focus of Tiziana Life Sciences' Phase 2 trial?

The Phase 2 trial focuses on evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS).

What is the ALS MyMatch Program mentioned by Tiziana Life Sciences?

The ALS MyMatch Program is a program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham, and Tiziana’s Phase 2 trial of intranasal foralumab in ALS has been accepted for inclusion in this program.

Does this Tiziana Life Sciences update include financial results?

No. The update describes the acceptance of Tiziana Life Sciences’ Phase 2 intranasal foralumab ALS trial into the ALS MyMatch Program and does not present financial results or transaction details.

When did Tiziana Life Sciences make this ALS trial announcement?

Tiziana Life Sciences made the announcement on November 25, 2025, and it is furnished as Exhibit 99.1 to the report.

Is the Tiziana Life Sciences press release part of this submission?

Yes. A press release titled “Tiziana Life Sciences LTD Press Release, dated November 25, 2025” is included as Exhibit 99.1 to the report.